Butyrophilins Role in Colon Cancer

Role of Butyrophilins in Colon Cancers Aggressiveness Evaluation

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04185272

Enrollment

200

Registered

2019-12-04

Start date

2020-06-30

Completion date

2028-06-30

Last updated

2025-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonic Cancer

Brief summary

quantification of BTNL molecules in colon cancer in order to determinate if their could be used as a prognostic marquer

Interventions

BIOLOGICALanalysis of BTN and BTNL status

analysis of BTN and BTNL expression in colon cancer and hepatic metastasis

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Intervention model description

colon cancer patients and metastatic colon cancer patients will be included in this study. We expect that BTNL molecules expression is different depending of the aggressiveness of the illness

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient is older than 18 years old, * Signed participation consent, * Non-metastatic colon cancer immediately resectable or metastatic and liver synchronous for which it was decided a combined colic and liver surgery (metastatic patient at the outset) in multidisciplinary consultation meeting. * Performance Status (PS) 0 or 1 * affiliated to the social security or beneficiary

Exclusion criteria

* Rectal cancer, colon cancer recurrence * Emergency of colon cancer Surgery * History of inflammatory disease of the digestive tract (Crohn's disease or ulcerative colitis) * Patient who received neoadjuvant therapy other than chemotherapy * Patient treated with immune-suppressors or long-course corticosteroids \<12 months * Pregnant women or likely to be pregnant (without effective contraception) or breastfeeding, * Person in urgent situation, person under legal protection measure, or unable to express his / her consent, * Impossibility of submitting to the medical examination of the test for geographical, social or psychological reasons

Design outcomes

Primary

Measure	Time frame	Description
evaluation of BTNL3, BTNL8 and BTNL9 expression by transcriptomics and immunohistochemistry	8 years	healthy and cancerous colon ad metastasis (if applicable) will be analysed by

Countries

France

Contacts

Primary ContactJihane PAKRADOUNI, PharmD,PhD

drci.up@ipc.unicancer.fr04 91 22 37 78

Backup ContactLaurie-Anne GOUTY, PhD

drci.up@ipc.unicancer.fr33491223778

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026